home / stock / xrtx / xrtx news

XRTX News and Press, XORTX Therapeutics Inc.

Stock Information
Company Name: XORTX Therapeutics Inc.
Stock Symbol: XRTX
Market: NASDAQ
Website: xortx.com
Menu
XRTX XRTX Quote XRTX Short XRTX News XRTX Articles XRTX Message Board
Get XRTX Alerts

News, Short Squeeze, Breakout and More Instantly...
XRTX - XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote "For" the Share Consolidation

Your vote is important –  Vote well in advance of the proxy voting deadline: March 20, 2026 XORTX’s board of directors unanimously recommends that Shareholders vote FOR all resolutions Shareholder questions or need voting assistance? Please contact Laurel Hill Advisory Gro...
XRTX - XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

CALGARY, Alberta, March 05, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney dise...

XRTX - XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressiv...

XRTX - XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disea...
XRTX - XORTX Announces Closing of US$1.1 Million Registered Direct Offering

CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidn...

XRTX - XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidn...

XRTX - XORTX Therapeutics gains 180-day extension from Nasdaq to regain $1.00 bid price compliance

2025-10-21 01:44:42 ET XORTX Therapeutics ( NASDAQ: XRTX ) has announced that it has received an extension notice from the Nasdaq Stock Market, granting the company an additional 180 days to meet the exchange’s minimum bid price requirement of $1.00 per share......
XRTX - XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidn...

XRTX - XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...

XRTX - US Companies Moving the Markets, Evening edition
Mon, Oct 20, 2025 as of 4:00 pm ET

A look at the top 10 most actives in the United States Beyond Meat Inc. (BYND) rose 127.7% to $1.47 on volume of 1,117,806,955 shares AiRWA Inc. (YYAI) fell 17.3% to $0.1001 on volume of 366,562,519 shares Adaptimmune Therapeutics plc (ADAP) fell 70.5% to $0.059 on volume of 318,840,954 sha...
Next 10